The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
Open accessAbstract
BACKGROUND: Alzheimer's disease is the most common cause of dementia and is characterised by an insidious onset and slow deterioration. The estimated prevalence of Alzheimer's disease for a standard health authority (500,000 people) is about 3330. Current service involves a wide range of agencies, and drug therapy for some patients. OBJECTIVES: To provide a rapid and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease. METHODS: A systematic review of the literature was undertaken. METHODS - DATA SOURCES: Searches were made of electronic databases, including MEDLINE, EMBASE, The Cochrane Library, Database of Abstracts of Reviews of Effectiveness, NHS Economic Evaluation Database, National Research Register, Science Citation Index, BIOSIS, EconLit, MRC Trials database, Early Warning System, Current Controlled Trials, TOXLINE, Index of Scientific and Technical Proceedings, and Getting Easier Access to Reviews. All sources were searched over the period covered by the databases up to March/July 2000. Bibliographies of related papers were assessed for relevant studies and experts were contacted for advice and peer review, and to identify additional published and unpublished references. Manufacturer submissions to the National Institute for Clinical Excellence (NICE) were reviewed. METHODS - STUDY SELECTION: Studies were included if they fulfilled the following criteria: (1) INTERVENTION: donepezil, rivastigmine or galantamine used to treat Alzheimer's disease. (2) PARTICIPANTS: people diagnosed with Alzheimer's disease who meet the criteria for treatment with donepezil, rivastigmine and galantamine. (3) OUTCOMES: measures assessing changes in cognition, function, behaviour and mood, quality of life (including studies assessing carer well-being and carer-input), and time to institutionalisation. (4) DESIGN: systematic reviews of randomised controlled trials (RCTs) and RCTs comparing donepezil, rivastigmine or galantamine with placebo or each other or non-drug comparators were included in the review of effectiveness. Economic studies of donepezil, rivastigmine or galantamine used to treat Alzheimer's disease that included a comparator (or placebo) and both the costs and consequence (outcomes) of treatment were included in the review of cost-effectiveness. Studies in non-English language, and abstracts and conference poster presentations of systematic reviews, RCTs and economic evaluations were excluded. Two reviewers identified studies by independently screening study titles and abstracts, and then by examining the full text of selected studies to decide inclusion. METHODS - DATA EXTRACTION AND QUALITY ASSESSMENT: Data extraction and quality assessment were undertaken by one reviewer and checked by a second reviewer, with any disagreements resolved through discussion. The quality of RCTs was assessed using the Jadad scale and the quality of systematic reviews was assessed using criteria developed by the NHS Centre for Reviews and Dissemination. The quality of economic evaluation studies was assessed by their internal validity (i.e. the methods used) using a standard checklist, and external validity (i.e. the generalisability of the economic study to the population of interest) using a series of relevant questions. METHODS - DATA SYNTHESIS: The clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine were synthesised through a narrative review with full tabulation of results of all included studies. In the economic evaluation, the reviewers assessed whether adjustments could be made to existing models to reflect the current situation in England and Wales. RESULTS - CLINICAL EFFECTIVENESS: (1) Donepezil--three systematic reviews and five RCTs (plus four studies from industry (unpublished data, submitted as commercial in confidence)) were found. Results suggest that donepezil is beneficial when assessed using global and cognitive outcome measures. (2) Rivastigmine--three systematic reviews and five RCTs (plus two studies from industry (unpublished data, submitted as commercial in confidence)) were found. Results suggest that rivastigmine is beneficial in terms of global outcome measures. (3) Galantamine--one systematic review and three RCTs (plus three studies from industry (unpublished data, submitted as commercial in confidence)) were found. Results suggest that galantamine is beneficial in terms of global, cognitive and functional scales. RESULTS - SUMMARY OF BENEFITS: It is difficult to quantify benefits from the evidence available in the literature. Statistically significant improvements in tests such as ADAS-cog (Alzheimer's Disease Assessment Scale cognitive subscale) may not be reflected in changes in daily life. (ABSTRACT TRUNCATED)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. L. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772808 · Cited by 285
Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited
Ladner, C. J., & Lee, J. M. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199808000-00001 · Cited by 142
Cited by
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Callahan, C. M., Boustani, M. A., Unverzagt, F. W., Austrom, M. G., Damush, T. M., Perkins, A. J., Fultz, B. A., Hui, S. L., Counsell, S. R., & Hendrie, H. C. (2006) · JAMA · doi:10.1001/jama.295.18.2148 · Cited by 798
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects
Kent, D. M., Steyerberg, E., & van Klaveren, D. (2018) · BMJ · doi:10.1136/bmj.k4245 · Cited by 479
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
A rational framework for decision making by the National Institute for Clinical Excellence (NICE)
Claxton, K., Sculpher, M., & Drummond, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09832-x · Cited by 456
Lamb, S. E., Sheehan, B., Atherton, N., Nichols, V., Collins, H., Mistry, D., Dosanjh, S., Slowther, A. M., Khan, I., Petrou, S., et al. (2018) · BMJ · doi:10.1136/bmj.k1675 · Cited by 417
Winkley, K., Landau, S., Eisler, I., & Ismail, K. (2006) · BMJ · doi:10.1136/bmj.38874.652569.55 · Cited by 359
Targeting the CREB pathway for memory enhancers
Tully, T., Bourtchouladze, R., Scott, R., & Tallman, J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1061 · Cited by 357
Burns, T., Catty, J., Dash, M., Roberts, C., Lockwood, A., & Marshall, M. (2007) · BMJ · doi:10.1136/bmj.39251.599259.55 · Cited by 343
Pembrey, M., Saffery, R., Bygren, L. O., & Network in Epigenetic Epidemiology (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102577 · Cited by 325
Galantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
AN ANALYSIS OF THE QUALITY OF CARTILAGE REPAIR STUDIES
JAKOBSEN, R. B., ENGEBRETSEN, L., & SLAUTERBECK, J. R. (2005) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200510000-00012 · Cited by 313
Three simple rules to ensure reasonably credible subgroup analyses
Burke, J. F., Sussman, J. B., Kent, D. M., & Hayward, R. A. (2015) · BMJ · doi:10.1136/bmj.h5651 · Cited by 312
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309
Griffin, D., Parsons, N., Shaw, E., Kulikov, Y., Hutchinson, C., Thorogood, M., Lamb, S. E., & for the UK Heel Fracture Trial (UK HeFT) investigators (2014) · BMJ · doi:10.1136/bmj.g4483 · Cited by 307
Mangal, S., Gao, W., Li, T., & Zhou, Q. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 288
Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R. M., Vansteenkiste, J., Thatcher, N., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.014 · Cited by 277
The serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Duclos, A., Peix, J.-L., Colin, C., Kraimps, J.-L., Menegaux, F., Pattou, F., Sebag, F., Touzet, S., Bourdy, S., Voirin, N., et al. (2012) · BMJ · doi:10.1136/bmj.d8041 · Cited by 261
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 260
Chan, A.-W., Hrobjartsson, A., Jorgensen, K. J., Gotzsche, P. C., & Altman, D. G. (2008) · BMJ · doi:10.1136/bmj.a2299 · Cited by 202
Harker, J., & Kleijnen, J. (2012) · International Journal of Evidence-Based Healthcare · doi:10.1111/j.1744-1609.2012.00290.x · Cited by 137
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Eiring, Ø., Landmark, B. F., Aas, E., Salkeld, G., Nylenna, M., & Nytrøen, K. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007848 · Cited by 57
Harvey, P. D., Hassman, H., Mao, L., Gharabawi, G. M., Mahmoud, R. A., & Engelhart, L. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0804 · Cited by 52
Saraf, M. K., Anand, A., & Prabhakar, S. (2010) · Neurochemical Research · doi:10.1007/s11064-009-0051-4 · Cited by 48
Metadata
- Authors
- Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N.
- Venue
- Health Technology Assessment
- Published
- 2001
- Volume
- 5
- Issue
- 1
- Pages
- 1-137
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2035343397
- Cited by
- 246
- References
- 3
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.